Search

Sarepta Therapeutics anuncia convocatoria de solicitudes para el 6.º Route 79 anual, el programa de becas Duchenne
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
Notice on Cookies
Privacy Policy
Community Letter: SRP-9001 Advisory Committee Meeting will be held
A Study of the Natural History of Participants With LGMD2E/​R4, LGMD2D/​R3, LGMD2C/​R5, and LGMD2A/​R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)